Xenetic Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc. on February 10, 2014, covering events occurring on February 7, 2014. The filing reports the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or operational metrics.
Material Changes
The primary material change reported is the appointment of Dr. Timothy R. Coté to the Board of Directors. Dr. Coté is a regulatory expert with 22 years of federal service, including as the Director of the FDA Office of Orphan Products Development (2007-2011).
Agreement Terms and Outlook
- Compensation: Dr. Coté will receive an annual fee of $25,000 paid quarterly, plus an additional annual fee between $3,000 and $10,000 for attending up to four board meetings.
- Equity Incentives: The agreement includes options to purchase up to 50,000 shares of common stock upon the occurrence of certain product milestones.
- Consulting Exclusivity: Dr. Coté's firm, Coté Orphan Consulting, LLC, holds the exclusive right to advise Xenetic on all orphan drug filings with the U.S. FDA for the duration of his board tenure.
- Risks and Contingencies: The filing states Dr. Coté has had no material direct or indirect interest in company transactions over the last two years, except as disclosed.
Investor Verification Checklist
- Verify the specific product milestones required to trigger the issuance of 50,000 stock options.
- Review the full text of the agreement (Exhibit 10.1) for additional terms not summarized in the 8-K.
- Confirm the impact of the exclusive consulting arrangement on future regulatory filing costs and strategy.
- Check subsequent filings for updates on the company's orphan drug pipeline progress.